Adaptimmune Therapeutics is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $0.48 – an increase of 2.19% over the previous day. Adaptimmune Therapeutics employs 534 staff and has a trailing 12-month revenue of around $71.1 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $0.42 up to $2.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.06. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Historical closes compared with the last close of $0.4752
| 1 week (2023-11-21) | 7.51% |
|---|---|
| 1 month (2023-10-28) | -13.60% |
| 3 months (2023-08-28) | -42.05% |
| 6 months (2023-05-28) | -56.40% |
| 1 year (2022-11-28) | -77.48% |
| 2 years (2021-11-28) | -88.32% |
| 3 years (2020-11-28) | -90.32% |
| 5 years (2018-11-28) | -92.01% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Adaptimmune Therapeutics P/E ratio, PEG ratio and EBITDA
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Everything we know about the Discord IPO, plus information on how to buy in.
Steps to owning and managing FND, with 24-hour and historical pricing before you buy.
Steps to owning and managing SWX, with 24-hour and historical pricing before you buy.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing KEG, with 24-hour and historical pricing before you buy.
Steps to owning and managing MDR, with 24-hour and historical pricing before you buy.
Steps to owning and managing GEN, with 24-hour and historical pricing before you buy.
Everything we know about the Grail IPO, plus information on how to buy in.
Steps to owning and managing HOG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.